| Name | Title | Contact Details |
|---|
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
Mar Cor Purification/Fluid Solutions is a Drexel Hill, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Celyad is a clinical-stage biopharmaceutical company focused on the identification and development of specialized cell based therapies. With product candidates in oncology and cardiology, Celyad seeks to address diseases with high unmet medical needs such as heart failure and cancer. Founded in 2007, Celyad leverages unique know-how in taking cell based therapies from bench to Phase III, as well as the manufacturing and logistical infrastructure for such complex products. Celyad builds it business model on partnering with prominent research institutions such as the Mayo Clinic and Dartmouth College, and develops those programs from bench to commercial applications.
BioCareSD is a specialty distributor of biological products for hemophilia, thrombophilia, immunology, critical care, and ALS. They are committed to providing customer-oriented solutions, unmatched service levels, and a unique distribution network to e...
Celera Corporation (Celera) is a healthcare business delivering personalized disease management through a combination of products and services. The Company operates in three segments: a clinical laboratory testing service business (Lab Services), a